Abstract

EFFICACY AND SAFETY OF CONCOMITANT ADMINISTRATION OF OMEGA-3 FATTY ACIDS AND SIMVASTATIN FOR TREATMENT DYSLIPIDEMIA IN IRAQI PATIENTS

Kawthar Faris Al-Tamimi*, Ibrahim Adham Majeed, Mowafaq MohammedGhareeb, Hassan Mohammed Al-Tamimi

ABSTRACT

Background: Dyslipidemia is an abnormal amount of lipids in the blood. The aim of this study was to evaluate the efficacy and safety of omega-3 fatty acids administered with or without simvastatin in dyslipidemia. Methods: Ninety patients with dyslipidemia were randomized into three groups; group (A) treated with 4gm/day Omega- 3, group (B) treated with 20 mg/day simvastatin, group (C) treated with a combination of 4gm/day Omega-3 and 10 mg/day simvastatin for 8 weeks. The evaluation includes determination of (TC, TG, LDLc, VLDL-c HDL-c, Reduced glutathione (GSH), Malondialdehyde (MDA), liver functions ( ALT, AST and Total bilirubin), and renal function (S. Urea, S. Creatinine, and micro albumin- urea). Also the body mass index (BMI) was evaluated at first visit as baseline and then after 8 weeks. Results: after 8 weeks of treatment, the results of group-A show significant reduction (p< 0.05) in the levels of TG, TC, VLDL-c, LDL/HDL ratio, and BMI with a significant elevation (p< 0.05) in HDL-c value, without any reported adverse effect, changes in liver function, and renal function, while group-B results in a significant reduction (p< 0.05) of TC and LDL-c, and LDL\HDL ratio. On the other hand the group-C results in a significant reduction in the levels of TG, TC, LDL, VLDL, LDL/HDL ratio, and BMI without increasing in the score of adverse effects. Conclusions: Omega-3 can be used effectively and safely in combination with Simvastatin to improve its effect in the treatment of dyslipidemia and prevent its observed adverse effect.

Keywords: Dyslipidemia, Omega-3, Simvastatin, Lipoproteins.